Scancell (LON:SCLP) Stock Price Down 8.9% – Should You Sell?

Scancell Holdings plc (LON:SCLP)’s share price traded down 8.9% on Monday . The company traded as low as GBX 7.72 ($0.10) and last traded at GBX 7.72 ($0.10). 395,448 shares were traded during trading, a decline of 51% from the average session volume of 801,264 shares. The stock had previously closed at GBX 8.47 ($0.11).

Scancell Price Performance

The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The firm’s 50-day moving average is GBX 8.94 and its two-hundred day moving average is GBX 11.77. The company has a market cap of £79.49 million, a P/E ratio of -11.77 and a beta of 0.35.

Scancell (LON:SCLP) last announced its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) EPS for the quarter. Analysts anticipate that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.